MS PARIS 2017
Les travaux publiés ayant utilisé les données de l’OFSEP ont été soumis au congrès MS Paris 2017 réunissant l’ACTRIMS et l'ECTRIMS (respectivement American et European Committee for Treatment and Research In Multiple Sclerosis), le plus gros congrès au monde consacré à la sclérose en plaques, qui s’est tenu à Paris en octobre dernier.
Au total, 18 communications scientifiques liées à l’OFSEP ont été acceptées.
Retrouvez ci-dessous le détail de ces communications, ainsi que les abstracts ou les posters associés.
P296 Double seronegative longitudinally extensive transverse myelitis: preliminary study on 17 patients. E. Maillart, Paris, FR
P301 Myelin oligodendrocyte glycoprotein antibodies predict a favourable outcome in neuromyelitis optica related disorders. A. Cobo-Calvo, Lyon, FR
P302 Myelin oligodendrocyte glycoprotein antibodies spectrum disorder: clinical features and prognostic factors in a cohort of 150 adult patients. A. Cobo-Calvo, Lyon, FR
P303 Prognostic factor for therapeutic response of attacks in anti-AQP4, anti-MOG seropositive and NMO seronegative patients. N. Collongues, Strasbourg, FR
P323 Characteristics of radiologically isolated syndrome (RIS) national French cohort. C. Lebrun-Frenay, Nice, FR
P335 Observatoire Français de la Sclérose en Plaques (OFSEP): a powerful epidemiological tool. R. Casey, Lyon, FR
P738 Big Multiple Sclerosis Data network: data sharing among five large MS registries. P. Iaffaldano, Bari, IT
P1149 Efficacy and safety of alemtuzumab in 150 patients with active relapsing-remitting MS: two-year follow-up in France. X. Ayrignac, Montpellier, FR
P1154 Efficacy of rituximab as a rescue therapy after the failure of second line treatment in relapsing remitting multiple sclerosis: a retrospective observational monocenter study. P. Durozard, Marseille, FR
P1237 Disease-modifying therapies use in primary progressive multiple sclerosis patients in France: data from the OFSEP cohort over the 1996 - 2017 period. E. Leray, Rennes, FR
P1854 Big Multiple Sclerosis Data Network: impact of early treatment on long term disability accumulation in relapsing remitting multiple sclerosis patients. P. Iaffaldano, Bari, IT
EP1302 Atypical Multiple Sclerosis and Idiopathic Inflammatory Demyelinating Diseases in a series of 74 consecutive cases. P. Labauge, Montpellier, FR
EP1335 Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France: data from the OFSEP database over the period 1996-2017. E. Leray, Rennes, FR
EP1555 OFSEP MRI protocol: the need of good practice’s standardization from clinicians to scientists. F. Cotton, Lyon, FR
EP1612 OFSEP biobank: high quality samples for powerful research on MS biomarkers. N. Dufay, Lyon, FR
EP1622 Comparative efficacy of Teriflunomide versus Dimethyl-Fumarate: a French multicenter observational study from the French national OFSEP cohort. D. Laplaud, Nantes, FR
EP1618 Two-year follow-up of 19 patients treated with alemtuzumab for active relapsing remitting MS: the Lyon’s experience. F. Durand Dubief, FR
Cliquez ici pour retourner à la page d'accueil du site de l'OFSEP.
